<DOC>
	<DOCNO>NCT01833546</DOCNO>
	<brief_summary>This Japanese Phase 1 , open-label , dose-escalating trial TH-302 monotherapy subject solid tumor combination gemcitabine subject pancreatic cancer .</brief_summary>
	<brief_title>A Japanese Phase 1 Trial TH-302 Subjects With Solid Tumors Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Phosphoramide Mustards</mesh_term>
	<criteria>At least 20 year age Signed write informed consent form Histologically cytologically confirm advanced metastatic solid tumor previously treat one standard treatment regimen ( ) effective therapy available Histologically cytologically confirm locally advanced unresectable metastatic pancreatic adenocarcinoma previously untreated chemotherapy systemic therapy Recovered toxicity prior anticancer treatment Grade 1 less Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 3 month Acceptable liver function , renal function , hematologic status coagulation status define protocol No clinically significant abnormality urinalysis Effective contraception male female subject risk conception exist Other inclusion criterion apply Prior anticancer treatment 3 myelosuppressive cytotoxic chemotherapy regimens Prior treatment gemcitabine advance metastatic pancreatic cancer , except radiosensitizing dos gemcitabine Prior radiotherapy 30 percent bone marrow within 6 month prior trial entry Cardiac disease New York Heart Association ( NYHA ) Class 3 4 , within 6 month prior trial entry Clinically significant ( , active ) cardiovascular disease Seizure disorder require anticonvulsant therapy Known brain , leptomeningeal epidural metastasis ( unless previously treat well control least 3 month trial entry ) Previously treat malignancy current disease least 5 year trial entry Severe chronic obstructive pulmonary disease major surgery , within 4 week prior trial entry , without complete recovery Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Anticancer treatment prior trial entry Participation investigational drug device trial within 4 week prior trial entry Known infection human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C A history allergic reaction Taking medication either moderate strong inhibitor inducer cytochrome P450 ( CYP ) 3A4 sensitive substrate cytochrome P450 Pregnancy lactation period Concomitant disease condition could interfere conduct trial , would , opinion Investigator , pose unacceptable risk subject trial Unwillingness inability comply trial protocol reason Legal incapacity limit legal capacity Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>TH-302</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>Evofosfamide</keyword>
</DOC>